Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02661100 | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients | withdrawn | Phase 1 / Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Dec 7, 2016 | clinicaltrials |
| NCT00450515 | Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer | withdrawn | Phase 2 | 0 | Alliance for Clinical Trials in OncologyOTHER | 0 | Dec 6, 2016 |
| NCT01479179 | Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Oct 26, 2016 | clinicaltrials |
| NCT02610621 | Safety and Efficacy of Sentinel Node Biopsy Omission for Breast Cancer Patients Who Plan to Have Adjuvant Chemotherapy | withdrawn | Phase 2 | 0 | Cedars-Sinai Medical CenterOTHER | 1 | Oct 13, 2016 | clinicaltrials |
| NCT02725541 | Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer(NATURE) | withdrawn | Phase 2 | 0 | Jenny C. Chang, MDOTHER | 1 | Sep 14, 2016 | clinicaltrials |
| NCT02539017 | The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer | withdrawn | Phase 2 | 0 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Aug 10, 2016 | clinicaltrials |
| NCT02338531 | Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer(RHEA) | withdrawn | Phase 2 | 0 | Jules Bordet InstituteOTHER | 2 | Apr 29, 2016 | clinicaltrials |
| NCT02215876 | Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 15, 2016 | clinicaltrials |
| NCT01410708 | TORI 104 Pre-Surgical Dasatinib | withdrawn | Phase 2 | 0 | AHS Cancer Control AlbertaOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT01985893 | Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer(THOR) | withdrawn | Phase 2 | 0 | Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V.OTHER | 1 | Jan 14, 2016 | clinicaltrials |
| NCT00343759 | Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy | withdrawn | Phase 2 | 0 | University of PennsylvaniaOTHER | 1 | Dec 11, 2015 | clinicaltrials |
| NCT00075413 | Arsenic Trioxide in Treating Women With Locally Advanced or Metastatic Breast Cancer | withdrawn | Phase 2 | 0 | The University of Texas Medical Branch, GalvestonOTHER | 0 | Oct 2, 2015 | clinicaltrials |
| NCT01501604 | BKM120 in Cancers With PIK3CA Activating Mutations | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 0 | Sep 17, 2015 | clinicaltrials |
| NCT02053597 | TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen(TRIUMPH) | withdrawn | Phase 2 | 0 | Jules Bordet InstituteOTHER | 1 | Sep 17, 2015 | clinicaltrials |
| NCT02396433 | Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers | withdrawn | Phase 1 / Phase 2 | 0 | The University of Texas Health Science Center at San AntonioOTHER | 0 | Aug 25, 2015 | clinicaltrials |
| NCT00022230 | Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Roger Williams Medical CenterOTHER | 1 | May 5, 2015 | clinicaltrials |
| NCT00678626 | Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer | withdrawn | Phase 2 | 0 | PfizerINDUSTRY | 0 | May 4, 2015 | clinicaltrials |
| NCT01008514 | Partial-Breast Radiation Therapy in Treating Women With Early-Stage Breast Cancer | withdrawn | Phase 2 | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 0 | Mar 26, 2015 | clinicaltrials |
| NCT00575978 | Hydralazine as Demethylating Agent in Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of ArkansasOTHER | 0 | Mar 4, 2015 | clinicaltrials |
| NCT01479946 | Electrochemotherapy For The Treatment Of Breast Cancer That Has Spread to the Skin | withdrawn | Phase 2 | 0 | Uppsala University HospitalOTHER | 1 | Dec 9, 2014 | clinicaltrials |
| NCT02115594 | Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer(ENCORE305) | withdrawn | Phase 2 | 0 | Syndax PharmaceuticalsINDUSTRY | 1 | Oct 8, 2014 | clinicaltrials |
| NCT01913067 | Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC(CRANIAL) | withdrawn | Phase 2 | 0 | Jules Bordet InstituteOTHER | 1 | Jul 24, 2014 | clinicaltrials |
| NCT01240941 | Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer | withdrawn | Phase 2 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Aug 20, 2013 | clinicaltrials |
| NCT00003455 | Antineoplaston Therapy in Treating Women With Advanced Breast Cancer | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00003536 | Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00080613 | Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer | withdrawn | Phase 2 | — | Robert H. Lurie Cancer CenterOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT01614184 | Fluorescein for Sentinel Lymph Node Biopsy (SLNB) in Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of UtahOTHER | 0 | Jul 10, 2013 | clinicaltrials |
| NCT01013506 | Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer | withdrawn | Phase 2 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | May 23, 2013 | clinicaltrials |
| NCT01612728 | Treatment for Joint Pains Due to Aromatase Inhibitor Therapy in Breast Cancer(AIA) | withdrawn | Phase 2 | 0 | Baylor Breast Care CenterOTHER | 0 | Feb 12, 2013 | clinicaltrials |
| NCT00227474 | S0348 Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Breast Cancer in Remission | withdrawn | Phase 2 | 0 | SWOG Cancer Research NetworkNETWORK | 0 | Jan 24, 2013 | clinicaltrials |
| NCT00217659 | S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer | withdrawn | Phase 2 | 0 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 3, 2013 | clinicaltrials |
| NCT01163929 | A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer | withdrawn | Phase 2 | 0 | University of KansasOTHER | 0 | Oct 24, 2012 | clinicaltrials |
| NCT00005614 | Management of Metastatic Breast Cancer in Frail Patients | withdrawn | Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Sep 25, 2012 | clinicaltrials |
| NCT00434031 | CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer(CETRA) | withdrawn | Phase 2 | 0 | National Cancer Institute, NaplesOTHER | 1 | Jul 30, 2012 | clinicaltrials |
| NCT01005641 | ELBA: Exemestane and Lapatinib in Advanced Breast Cancer(ELBA) | withdrawn | Phase 2 | 0 | National Cancer Institute, NaplesOTHER | 1 | Jul 13, 2012 | clinicaltrials |
| NCT00054470 | Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer | withdrawn | Phase 2 | 0 | The University of Texas Health Science Center at San AntonioOTHER | 0 | Jun 29, 2012 | clinicaltrials |
| NCT00057993 | Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer | withdrawn | Phase 2 | 0 | Northwestern UniversityOTHER | 0 | Jun 11, 2012 | clinicaltrials |
| NCT01288092 | BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Jun 7, 2012 | clinicaltrials |
| NCT00935558 | Dendritic Cell Based Therapy for Breast Cancer Patients | withdrawn | Phase 2 | 0 | Inge Marie SvaneOTHER | 1 | May 31, 2012 | clinicaltrials |
| NCT01169870 | Genexol-PM Versus Paclitaxel in Anthracycline-pretreated Metastatic Breast Cancer Patients | withdrawn | Phase 2 | 0 | National Cancer Center, KoreaOTHER_GOV | 0 | Jan 4, 2012 | clinicaltrials |
| NCT01229605 | Cyclophosphamide and Docetaxel Every 3 Weeks as Neoadjuvant Therapy in Locally Advanced Breast Cancer | withdrawn | Phase 2 | 0 | Tufts Medical CenterOTHER | 0 | Dec 12, 2011 | clinicaltrials |
| NCT01100489 | Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 8, 2011 | clinicaltrials |
| NCT00252811 | A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer | withdrawn | Phase 2 | 60 | AstraZenecaINDUSTRY | 1 | Jan 28, 2011 | clinicaltrials |
| NCT00006261 | Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast Cancer | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 10, 2010 | clinicaltrials |
| NCT00627627 | A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer | withdrawn | Phase 1 / Phase 2 | 56 | MedImmune LLCINDUSTRY | 1 | Feb 3, 2010 | clinicaltrials |
| NCT00712621 | Determining Quality of Life in Breast Cancer Patient After Completing Radiation,Chemotherapy,Surgery or Combination | withdrawn | Phase 2 | 460 | American Scitech InternationalOTHER | 1 | Nov 24, 2009 | clinicaltrials |
| NCT00380835 | Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer | withdrawn | Phase 2 | 66 | Celgene CorporationINDUSTRY | 1 | Sep 23, 2008 | clinicaltrials |
Data updated 23 days agoSource updated Dec 7, 2016source: clinicaltrials